Friday, 15 Nov 2019

RA/Inflammatory arthritis

Datesort ascending Type Title Save
21 Jun 2019 Social "Clinicians should assess test results based on the person's likelihood of infection and risk for progression to TB disease, if infected," according to the CDC. MMWR. 2019;68:552-553. https://t.co/eJGOHVCbkO
21 Jun 2019 ACR Video Dr. Gerd Burmester reviews the SEMIRA study from EULAR 2019
21 Jun 2019 ACR Video Riociquat in Scleroderma ILD
20 Jun 2019 Social FORWARD, a National Databank study, looked at malignancies & infections in RA pts starting abatacept, other biologicsor DMARDs. No difference in cancer risks, but ABA had lower risk hospitalized infx (HR 0.37) & lower infusion/injx rxn than other biologics https://t.co/9GonhVTK3Z
19 Jun 2019 Slide of the day AOSD Diagnostic Criteria
19 Jun 2019 Social #EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/5K58IUNdCV
18 Jun 2019 News Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis
17 Jun 2019 Social RT @drdavidliew: Pilot vagal nerve stimulation for RA: interesting with clinical and immunological response, but surgical complications and…
17 Jun 2019 Social RT @sclerodermaUM: Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acute phase reactants.…
17 Jun 2019 Social RT @sclerodermaUM: Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single dose. —there were more…
17 Jun 2019 Social RT @sclerodermaUM: Vagal nerve stimulation for management of RA. Effective in refractory RA #EULAR2019 https://t.co/petEUKty7v
17 Jun 2019 Social RT @Janetbirdope: Can implanting vagal nerve stimulator in tough to treat RA pts work? Could theoretically decrease TNF. Small RCT. Maybe.…
17 Jun 2019 Social RT @tuna0sashimi: #eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded RA <2y study). Now “Ear…
17 Jun 2019 Social RT @Janetbirdope: EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new…
17 Jun 2019 Social RT @Janetbirdope: Eular highlights. RA guidelines still mostly like before - all MOA drugs ok after MTX and still taper if sustained remiss…
12 Jun 2019 News EULAR 2019 - Day 1 Report
06 Jun 2019 Social RT @KDAO2011: Word of the day: Ischuria= urinary retention. My patient with systemic sclerosis and severe spinal stenosis developed ischu…
06 Jun 2019 News Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis
06 Jun 2019 ACR Video RheumNow Live Preview with Dr. Michael Holers (Insights into Preclinical RA)
06 Jun 2019 Social Korean Natl Claims Database examined RA & risk of opportunistic infx- OI, H zoster & candidiasis are seen in early RA. SIR for OI in early RA=1.14 (95% CI, 1.05‐1.23). H zoster (1.12), candidiasis (2.40); Age, steroids & comorbidity increased OI risk https://t.co/U7LPMpmPqG